takeover target, page-14

  1. 63 Posts.
    lightbulb Created with Sketch. 27
    great question.
    I don't think Lilly would care for ACR as they are too big and probably spend 50x more on their R&D than ACR standalone, I see Mayne Pharma as a company that might find ACR interesting as they are partially competing in the same topical space.
    Also I would have thought ACR would have been far more attractive 2 years ago when it had 30+ million in bank, maybe Dobinson got a call from a potential suitor but like always he was asleep at the wheel.
    CEO has great pharma connections so if a suitor was around he would know about it.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.7¢
Change
0.000(0.00%)
Mkt cap ! $6.931M
Open High Low Value Volume
1.7¢ 1.7¢ 1.7¢ $8.531K 501.7K

Buyers (Bids)

No. Vol. Price($)
2 304269 1.6¢
 

Sellers (Offers)

Price($) Vol. No.
1.8¢ 552359 3
View Market Depth
Last trade - 10.48am 25/06/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.